Protein Kinase Inhibitors: all 15,147 studies that test it

Page 32 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung CancerActive, not recruitingNCT04216316Phase 1/2Results posted
• Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesTerminatedNCT04214418Phase 1/2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingNCT04211337Phase 3Results posted
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2Results posted
• Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
• A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.TerminatedNCT04209465Phase 1Results posted
• Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast CancerCompletedNCT04205903Phase 1Results posted
• Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment FailureCompletedNCT04205799Phase 2Results posted
• Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedNCT04204902Phase 1Results posted
• Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT04204057Phase 2Results posted
• Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor PathwayCompletedNCT04200911Early Phase 1Results posted
• Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaActive, not recruitingNCT04200443Phase 2Results posted
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedNCT04199104Phase 3Results posted
• Acalabrutinib for the Treatment of Chronic Graft Versus Host DiseaseActive, not recruitingNCT04198922Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsTerminatedNCT04198818Phase 1/2Results posted
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3Results posted
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingNCT04197713Phase 1Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT04195698Phase 3Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Phase 3Results posted
• A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Phase 1/2Results posted
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2Results posted
• A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT04191499Phase 2/3Results posted
• Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
• Futibatinib in Patients With Specific FGFR AberrationsTerminatedNCT04189445Phase 2Results posted
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT04177108Phase 3Results posted
• CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerActive, not recruitingNCT04176848Phase 2Results posted
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial SpondyloarthritisCompletedNCT04169373Phase 3Results posted
• Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)TerminatedNCT04169074Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results posted
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04163718Phase 2Results posted
• A Phase II Study in Adult Patients With Moderate to Severe Atopic DermatitisCompletedNCT04162899Phase 2Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• Enhancing Self Regulation Among SmokersCompletedNCT04161144Phase 2Results posted
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedNCT04159896Phase 2Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory OsteosarcomaCompletedNCT04154189Phase 2Results posted
• Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedNCT04149821Phase 2Results posted
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted
• A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788CompletedNCT04132050Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative ColitisTerminatedNCT04130919Phase 2Results posted
• PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedNCT04129931Phase 2Results posted
• Palbociclib + Ganitumab In Ewing SarcomaTerminatedNCT04129151Phase 2Results posted
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
• Sitravatinib in Metastatic Breast CancerTerminatedNCT04123704Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)TerminatedNCT04119453Phase 2Results posted
• Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerActive, not recruitingNCT04117945Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyTerminatedNCT04115839Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTerminatedNCT04115748Phase 3Results posted
• Dasatinib In Waldenström MacroglobulinemiaTerminatedNCT04115059Phase 1Results posted
• An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSUCompletedNCT04109313Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedNCT04108858Phase 1/2Results posted
• Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
• Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN PatientsTerminatedNCT04103645Phase 2Results posted
• Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR AlterationsActive, not recruitingNCT04096417Phase 2Results posted
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsTerminatedNCT04093362Phase 3Results posted
• A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)CompletedNCT04093024Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedNCT04092452Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingNCT04088409Phase 3Results posted
• Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaTerminatedNCT04088188Phase 1Results posted
• A Study of Baricitinib in Participants With Rheumatoid ArthritisCompletedNCT04086745Phase 4Results posted
• A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein OcclusionCompletedNCT04085341Phase 2Results posted
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene AlterationsCompletedNCT04083976Phase 2Results posted
• Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedNCT04079738Phase 1/2Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04075396Phase 1/2Results posted
• Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT04075292Phase 3Results posted
• A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT04072952Phase 1/2Results posted
• Study of Safety and Proof of the Mechanism of BLZ945 in ALS PatientsTerminatedNCT04066244Phase 2Results posted
• Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedNCT04066114Phase 1/2Results posted
• Everolimus Monotherapy as Immunosuppression After Liver TransplantTerminatedNCT04063865Phase 3Results posted
• Senolytic Therapy to Modulate Progression of Alzheimer's DiseaseCompletedNCT04063124Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2Results posted
• A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerTerminatedNCT04060862Phase 1Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)CompletedNCT04057573Phase 3Results posted
• A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.CompletedNCT04057118Phase 2Results posted
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic FunctionCompletedNCT04056468Phase 1Results posted
• A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy KidneysCompletedNCT04056455Phase 1Results posted
• Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)CompletedNCT04056195Phase 2Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)CompletedNCT04052425Phase 3Results posted
• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1Results posted
• RAPA-Keloid Study of Keloid RegressionCompletedNCT04049552Early Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/2Results posted
• A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)CompletedNCT04042376Phase 4Results posted
• A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedNCT04038359Phase 2Results posted
• A Renal Impairment Study for PF-06651600TerminatedNCT04037865Phase 1Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Study of Evobrutinib in Participants With RMSTerminatedNCT04032171Phase 3Results posted
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedNCT04032158Phase 3Results posted
• LY3023414 and Prexasertib in Metastatic Triple-negative Breast CancerCompletedNCT04032080Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results posted

← Protein Kinase Inhibitors overview